Prof. Dennis Gillingham receives one of the coveted ERC Consolidator Grants from the European Research Council (ERC). In his research project, Prof. Dennis Gillingham studies how small molecules can take advantage of the genomic instability of cancer. Genomic instability is a hallmark of cancer because it provides the means for rapid evolution. However, this very instability also creates unique vulnerabilities in cancer that can be exploited. The ERC project proposes to create small molecules that can infiltrate and reprogram signaling events that occur around sites of DNA damage or when DNA replication stalls. Such events occur frequently in genetically unstable cells, therefore this approach should deliver selectively toxic molecules that may be relevant for the development of new therapeutics. Gillingham` s project is funded with 1.9 Million Euros over five years. Source:

Céline Wittwer, SCS